Ocata Therapeutics Inc news

   Watch this stock
Showing stories 1 - 10 of about 82   

Articles published

OCAT 0.0000
price chart
Advanced Cell Technology Changes Name to Ocata Therapeutics
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc., (OTCBB: OCAT) today announced the change of its company name to Ocata Therapeutics, Inc., effective immediately. The change, which has been approved by the Company's ...
Related articles »  
Ocata Therapeutics (OCAT) to be Acquired by Astellas in $379M Deal
Astellas Pharma Inc. and Ocata Therapeutics, Inc. (NASDAQ: OCAT) announced today that they have entered into a definitive agreement.
Astellas Pharma Joins Hands With Ocata Therapeutics  Bidness ETC
Ocata Shareholder Majority Rejects Astellas Offer As Woefully Inadequate
Ocata Therapeutics majority shareholders (NASDAQ: OCAT) have again, after this third offer, indicated that its Board of Directors has erred in its unanimous recommendation for the solicited tender offer by Astellas to acquire all of the outstanding ...
Sorting Out Ocata Management's Words And Deeds
What has bothered me about the recent lowball tender offer by Astellas Pharma, Inc. on November 9, 2015, are the apparent statements by the executives of Advanced Cell Technology/Ocata Therapeutics, both past and present, compared with their actions.
DALLAS--(BUSINESS WIRE)--Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Ocata Therapeutics, ...
Ocata Therapeutics (OCAT) Stock Declines After Pricing $30 Million Share Offering
"We rate OCATA THERAPEUTICS INC (OCAT) a SELL. This is based on the dominance of unfavorable investment measures, which should drive this stock to significantly underperform the majority of stocks that we rate.
Ocata Therapeutics Announces Pricing of $30 Million Offering of Common Stock ...  Business Wire (press release)
Ocata Therapeutics Announces Positive Results Reported in a Late Breaking ...
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, announced today that data will be presented in a Late Breaking Abstract at the ...
Ocata Therapeutics: Are You Watching A Bluebird Go By?
Biotechnology investors are all looking for that mythical market-cap event multiplier that is long in the making and comes by surprise.
Ocata Therapeutics Science For The Lay Person
To understand the value of Ocata Therapeutics (NASDAQ:OCAT), it is important to hear, and read, what its Chief Scientific Officer has to say about his research, as well as some of their clinical trial investigators.
Astellas Pharma $8.50 Tender Offer For Ocata Therapeutics Offer Fails Again
The ongoing battle for control of Ocata Therapeutics (NASDAQ:OCAT) inched closer to completion today as an SEC filing reveals that 47% of outstanding shares have been tendered in response to the November 19, 2015 tender offer by Japan based ... Since ...
Astellas Extends Tender Offer for Ocata Therapeutics Again  Genetic Engineering & Biotechnology News (press release)